In this article:

B.Riley Financial Thinks Seelos Therapeutics’ Stock is Going to Recover

In this article:
In this article:

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Seelos Therapeutics (SEELResearch Report) today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.20, close to its 52-week low of $1.00.

According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -19.6% and a 28.4% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.

Seelos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $6.60 and a one-year low of $1.00. Currently, Seelos Therapeutics has an average volume of 2.36M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Its portfolio include late-stage clinical assets targeting psychiatric and movement disorders. The company is headquartered in New York, NY.

Read More on SEEL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed